Hims & Hers stock rises 14% as FDA schedules peptide compounding review FDA Targets GLP 1 and Peptide Compounding, Advertising and 'Research Use Only' Labeling The U.S. Food and Drug Administration is moving toward allowing compounding pharmacies to produce more than a dozen injectable peptides that were banned because of potentially significant safety risks, the New York BPC 157 The Healing Peptide